Glaucoma is the leading cause of blindness worldwide. Recent advances in the treatment of glaucoma have improved intraocular pressure reduction and increased length of therapy release compared to traditional treatment options. However, poor patient treatment compliance and the resulting permanent vision loss due to retinal ganglion cell (RGC) death remains a significant problem. A team led by Dr. Ram Nagaraj has developed a gene therapy for the prevention of RGC death in the setting of glaucoma. In vivo glaucoma mouse models showed 41% reduced RGC death with a single gene therapy intravitreal injection compared to controls. The inventors believe their therapy can provide long term RGC protection for patients with or at risk of glaucoma.
Download Summary Document Here:
http://cuamc.technologypublisher.com/files/sites/cu5168h_ncs_updated.pdf